STOCK TITAN

Sage Therapeutics, Inc - $SAGE STOCK NEWS

Welcome to our dedicated page for Sage Therapeutics news (Ticker: $SAGE), a resource for investors and traders seeking the latest updates and insights on Sage Therapeutics stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Sage Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Sage Therapeutics's position in the market.

Rhea-AI Summary
Sage Therapeutics reported business highlights and financial results for the third quarter ended September 30, 2023. The company announced the expected wholesale acquisition cost of ZURZUVAE to be $15,900, with the product becoming commercially available in December 2023. Sage also provided updates on their neuropsychiatry pipeline, including the progress of SAGE-718 and SAGE-324. Financially, the company's cash, cash equivalents, and marketable securities totaled $876 million as of September 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.75%
Tags
-
Rhea-AI Summary
Sage Therapeutics to host webcast to review Q3 2023 financial results and business updates
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.03%
Tags
conferences earnings
-
Rhea-AI Summary
Sage Therapeutics receives FDA Orphan Drug Designation for SAGE-718 in the treatment of Huntington's disease
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.16%
Tags
Rhea-AI Summary
Sage Therapeutics to present at investor conferences in September
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.34%
Tags
conferences
-
Rhea-AI Summary
Sage Therapeutics plans to reorganize its business operations and pipeline priorities to support long-term growth. They will launch ZURZUVAE for postpartum depression in late 2023. A 40% workforce reduction will be implemented. The company expects annualized net savings of $240 million and a non-recurring charge of $36-38 million. They have cash, cash equivalents, and marketable securities of $1.0 billion to support operations into 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.42%
Tags
none
-
Rhea-AI Summary
Sage Therapeutics, Inc. (SAGE) reported FDA approval of ZURZUVAE as the first oral treatment for postpartum depression (PPD) in adults, with a planned launch in Q4 2023. The company also highlighted its financial position with $1.0 billion in cash, cash equivalents, and marketable securities as of June 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-53.6%
Tags
Rhea-AI Summary
Sage Therapeutics, Inc. (Nasdaq: SAGE) will host a live webcast on August 7, 2023, at 8:00 a.m. ET to provide a business update and announce second quarter 2023 financial results. The webcast can be accessed on the Investor page of Sage’s website at investor.sagerx.com.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.24%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.19%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.35%
Tags
Sage Therapeutics, Inc

Nasdaq:SAGE

SAGE Rankings

SAGE Stock Data

838.94M
47.55M
12.56%
95.55%
14.31%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
CAMBRIDGE

About SAGE

sage therapeutics is a neuroscience-focused company developing medicines to treat life-threatening, rare cns disorders. our mission is to make life better for patients with central nervous systems diseases by discovering, developing, and delivering important new medicines to the market. to achieve that mission we leverage compelling science, a robust clinical foundation, strong partnerships, and a world-class team of founders, advisors, investors, scientists and managers. sage’s lead program, sage-547, is in clinical development for super-refractory status epilepticus (srse) and is the first of many compounds the company is developing in its portfolio of potential seizure medicines. sage’s robust chemistry platform has generated multiple new compounds that target the gabaa and nmda receptors, which have demonstrated preclinical activity. sage therapeutics is a private company launched in 2010 by an experienced team of r&d leaders, cns experts and investors.